Lactase persistence and ovarian carcinoma risk in Finland, Poland and Sweden

International Journal of Cancer

Volumn 117, Issue 1, 2005, Pages 90-94

  Kuokkanen, Mikko ^a,b   Butzow, Ralf ^c   Rasinperä, Heli ^b   Medrek, Krzysztof ^d   Nilbert, Mef ^e   Malander, Susanne ^e   Lubinski, Jan ^d   Järvelä, Irma ^b,c  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d POMERANIAN MEDICAL UNIVERSITY   (Poland)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

C T 13910 polymorphism; Epithelial ovarian cancer; Finland; Lactase persistence; Poland; Sweden

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GALACTOSE; LACTASE; LACTOSE;

ARTICLE; CANCER MORTALITY; CANCER RISK; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DAIRY PRODUCT; FEMALE; FINLAND; GENOTYPE; HISTOPATHOLOGY; HUMAN; HYDROGEN BREATH TEST; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CARCINOMA; POLAND; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; SWEDEN;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; FEMALE; FINLAND; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LACTASE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLAND; POLYMERASE CHAIN REACTION; RISK FACTORS; SWEDEN;

EID: 24644436926     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21130     Document Type: Article

References (67)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
2. World Cancer Research Fund, American Institute for Cancer Research. Ovary, food, nutrition and the prevention of cancer: a global perspective. Washington, DC. American Institute for Cancer Research. 1997, p 288-93.
3. Runnebaum IB, Stickeier E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001;127:73-9.
4. Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, Felix JC, Kreienberg R, el-Naggar A, Press MF. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 1999; 18:29-41.
5. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
6. Van Der Looij M, Szabo C, Besznyak I, Liszka G, Csokay B, Pulay T, Toth J, Devilee P, King MC, Olah E. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Im J Cancer 2000;86:737-40.
7. Malander S, Ridderheim M, Masback A, Loman N, Kristoffersson U, Olsson H, Nilbert M, Borg A. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer 2004;40:422-8.
8. Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, Boyd J. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998;178:670-7.
9. Sarantaus L, Vahteristo P, Bloom E, Tamminen A, Unkila-Kallio L, Butzow R, Nevanlinna H. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients. Eur J Hum Genet 2001;9:424-30.
10. Matsushima M, Kobayashi K, Emi M, Saito H, Saito J, Suzumori K, Nakamura Y. Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Hum Mol Genet 1995;4:1953-6.
11. Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, Easton D, Ponder BA. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997;336:1125-30.
12. Møller P, Heimdal K, Apold J, Fredriksen Å, Borg Å, Hovig E, Hagen A, Hagen B, Pedersen JC, Maehle L. Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer 2001;37:2428-34.
13. Menkiszak J, Gronwald J, Gorski B, Jakubowska A, Huzarski T, Byrski T, Foszczynska-Kloda M, Haus O, Janiszewska H, Perkowska M, Brozek I, Grzybowska E. et al. Hereditary ovarian cancer in Poland. Int J Cancer 2003;106:942-5.
14. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1212-20.
15. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993;270: 2813-8.
16. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-86.
17. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968;40:43-68.
18. Kaufman FR, Kogut MD, Donnell GN, Goebelsmann U, March C, Koch R. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med 1981;304:994-8.
19. Xu YK, Ng WG, Kaufman FR, Lobo RA, Donnell GN. Galactose metabolism in human ovarian tissue. Pediatr Res 1989;25:151-5.
20. Reichardt JK, Woo SL. Molecular basis of galactosemia: mutations and polymorphisms in the gene encoding human galactose-1-phosphate uridylyltransferase. Proc Natl Acad Sci USA 1991;88:2633-7.
21. Harlow BL, Cramer DW, Geller J, Willett WC, Bell DA, Welch WR. The influence of lactose consumption on the association of oral contraceptive use and ovarian cancer risk. Am J Epidemiol 1991;134: 445-53.
22. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.
23. Leslie ND. Insights into the pathogenesis of galactosemia. Annu Rev Nutr 2003;23:59-80.
24. Swartz WJ, Mattison DR. Galactose inhibition of ovulation in mice. Fertil Steril 1988;49:522-6.
25. Chen YT, Mattison DR, Feigenbaum L, Fukui H, Schulman JD. Reduction in oocyte number following prenatal exposure to a diet high in galactose. Science 1981;214:1145-7.
26. Simoons FJ. The geographic hypothesis and lactose malabsorption. A weighing of the evidence. Am J Dig Dis 1978;23:963-80.
27. Cramer DW. Lactase persistence and milk consumption as determinants of ovarian cancer risk. Am J Epidemiol 1989;130:904-10.
28. Meloni GF, Colombo C, La Vecchia C, Ruggiu G, Mannazzu MC, Ambrosini G, Cherchi PL. Lactose absorption in patients with ovarian cancer. Am J Epidemiol 1999;150:183-6.
29. Risch HA, Jain M, Marrett LD, Howe GR. Dietary lactose intake, lactose intolerance, and the risk of epithelial ovarian cancer in southern Ontario (Canada). Cancer Causes Control 1994;5:540-8.
30. Herrinton LJ, Weiss NS, Beresford SA, Stanford JL, Wolfla DM, Feng Z, Scott CR. Lactose and galactose intake and metabolism in relation to the risk of epithelial ovarian cancer. Am J Epidemiol 1995;141:407-16.
31. Arola H. Diagnosis of hypolactasia and lactose malabsorption. Scand J Gastroenterol Suppl 1994;202:26-35.
32. Rasinperä H, Savilahti E, Enattah NS, Kuokkanen M, Totterman N, Lindahl H, Järvelä I, Kolho KL. A genetic test which can be used to diagnose adult-type hypolactasia in children. Gut 2004;53:1571-6.
33. Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Järvelä I. Identification of a variant associated with adult-type hypolactasia. Nat Genet 2002;30:233-7.
34. Kuokkanen M, Enattah NS, Oksanen A, Savilahti E, Orpana A, Järvelä I. Transcriptional regulation of the lactase-phlorizin hydrolase gene by polymorphisms associated with adult-type hypolactasia. Gut 2003;52:647-52.
35. Olds LC, Sibley E. Lactase persistence DNA variant enhances lactase promoter activity in vitro: functional role as a cis regulatory element. Hum Mol Genet 2003;12:2333-40.
36. Troelsen JT, Olsen J, Moller J, Sjostrom H. An upstream polymorphism associated with lactase persistence has increased enhancer activity. Gastroenterology 2003;125:1686-94.
37. Syvänen AC, Aalto-Setälä K, Harju L, Kontula K, Söderlund H. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics 1990;8:684-92.
38. Socha J, Ksiazyk J, Flatz G, Flatz SD. Prevalence of primary adult lactose malabsorption in Poland. Ann Hum Biol 1984;11:311-6.
39. Nilsson TK, Johansson CA. A novel method for diagnosis of adult hypolactasia by genotyping of the -13910 C/T polymorphism with Pyrosequencing technology. Scand J Gastroenterol 2004;39:287-90.
40. Cramer DW, Greenberg ER, Titus-Ernsioff L, Liberman RF, Welch WR, Li E, Ng WG. A case-control study of galactose consumption and metabolism in relation to ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000;9:95-101.
41. Goodman MT, Wu AH, Tung KH, McDuffie K, Kolonel LN, Nomura AM, Terada K, Wilkens LR, Murphy S, Hankin JH. Association of dairy products, lactose, and calcium with the risk of ovarian cancer. Am J Epidemiol 2002;156:148-57.
42. Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, Hernandez-Avila M. Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico. Oncology 2002;63:151-7.
43. Yen ML, Yen BL, Bai CH, Lin RS. Risk factors for ovarian cancer in Taiwan: a case-control study in a low-incidence population. Gynecol Oncol 2003;89:318-24.
44. Goodman MT, Wu AH, Tung KH, McDuffie K, Cramer DW, Wilkens LR, Terada K, Reichardt JK, Ng WG. Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer. Am J Epidemiol 2002;156:693-701.
45. Obermayer-Pietsch BM, Bonelli CM, Walter DE, Kuhn RJ, Fahrleitner-Pammer A, Berghold A, Goessler W, Stepan V, Dobnig H, Leb G, Renner W. Genetic predisposition for adult lactose intolerance and relation to diet, bone density, and bone fractures. J Bone Miner Res 2004;19:42-7.
46. The World Dairy Situation. Bulletin of the International Dairy Federation 384/2003, 2003.
47. Kushi LH, Mink PJ, Folsom AR, Anderson KE, Zheng W, Lazovich D, Sellers TA. Prospective study of diet and ovarian cancer. Am J Epidemiol 1999;149:21-31.
48. Fairfield KM, Hunter DJ, Colditz GA, Fuchs CS, Cramer DW, Speizer FE, Willett WC, Hankinson SE. A prospective study of dietary lactose and ovarian cancer. Int J Cancer 2004; 110:271-7.
49. Mettlin CJ, Piver MS. A case-control study of milk-drinking and ovarian cancer risk. Am J Epidemiol 1990;132:871-6.
50. Pan SY, Ugnat AM, Mao Y, Wen SW, Johnson KC. A case-control study of diet and the risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1521-7.
51. Engle A, Muscat JE, Harris RE. Nutritional risk factors and ovarian cancer. Nutr Cancer 1991;15:239-47.
52. Webb PM, Bain CJ, Purdie DM, Harvey PW, Green A. Milk consumption, galactose metabolism and ovarian cancer (Australia). Cancer Causes Control 1998;9:637-44.
53. Britton JA, Westhoff C, Howe GR, Gammon MD. Lactose and benign ovarian tumors in a case-control study. Br J Cancer 2000;83:1552-5.
54. National Nutrition Council. Finnish Nutrition Recommendations. Helsinki: Ministry of Agriculture and Forestry, 1999. 32 p.
55. Miettinen S, Ahonen MH, Lou YR, Manninen T, Tuohimaa P, Syvälä H, Ylikomi T. Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells. Int J Cancer 2004;108:367-73.
56. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer 2000;86:40-6.
57. Bidoli E, La Vecchia C, Talamini R, Negri E, Parpinel M, Conti E, Montella M, Carbone MA, Franceschi S. Micronutrients and ovarian cancer: a case-control study in Italy. Ann Oncol 2001;12:1589-93.
58. Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol 1994;23:1133-6.
59. Tzonou A, Hsieh CC, Polychronopoulou A, Kaprinis G, Toupadaki N, Trichopoulou A, Karakatsani A, Trichopoulos D, Diet and ovarian cancer: a case-control study in Greece. Int J Cancer 1993;55:411-4.
60. Takeuchi A, Okano T, Ishida Y, Kobayashi T. Effects of dietary vitamin D intake on plasma levels of parathyroid hormone and vitamin D metabolites in healthy Japanese. Miner Electrolyte Metab 1995;21: 217-22.
61. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998;351:805-6.
62. McCarty MF. Parathyroid hormone may be a cancer promoter-an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D. Med Hypotheses 2000;54:475-82.
63. Cramer DW, Harlow BL, Willett WC, Welch WR, Bell DA, Scully RE, Ng WG, Knapp RC. Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet 1989;2: 66-71.
64. Elsas LJ, Dembure PP, Langley S, Paulk EM, Hjelm LN, Fridovich-Keil J. A common mutation associated with the Duarte galactosemia allele. Am J Hum Genet 1994;54:1030-6.
65. Langley SD, Lai K, Dembure PP, Hjelm LN, Elsas LJ. Molecular basis for Duarte and Los Angeles variant galactosemia. Am J Hum Genet 1997;60:366-72.
66. Morland SJ, Jiang X, Hitchcock A, Thomas EJ, Campbell IG. Mutation of galactose-1-phosphate uridyl transferase and its association with ovarian cancer and endometriosis. Int J Cancer 1998;77:825-7.
67. Cozen W, Peters R, Reichardt JK, Ng W, Felix JC, Wan P, Pike MC. Galactose-1-phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption, and the risk of borderline and invasive ovarian cancer (United States). Cancer Causes Control 2002;13:113-20.